投资者关系活动记录表 证券代码：300181 证券简称：佐力药业 编号：2024-019 浙江佐力药业股份有限公司 | --- | --- | --- | --- | |-----------------------|-----------------------------------------------------|----------------------------------------|---------------------------------------------------------| | | | | | | 投资者关系活动 | □特定对象调研 | □分析师会议 | | | 类别 | □媒体采访 | □业绩说明会 | | | | □新闻发布会 | □路演活动 | | | | □现场参观 | | | | | 其他（线上会议） | | | | 参与单位名称及 | | | 鹏华基金：李建国；长安基金：肖洁、朱施乐；博时基金：张 | | 人员姓名 | | 治业；东吴医药：李倩；长江医药：张楠。 | 中银基金：黄珺、廖冯昌、李文广；广发医药：李桠桐。 | | 时间 | 2024 年 1 ...

投资者关系活动记录表 证券代码：300181 证券简称：佐力药业 编号：2024-018 浙江佐力药业股份有限公司 | --- | --- | --- | |----------------------------|-------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------| | | | | | 投资者关系活动 | □特定对象调研 | □分析师会议 | | 类别 | □媒体采访 | □业绩说明会 | | | □新闻发布会 | ☑路演活动 | | | ☑ 现场参观 | | | | 其他 | | | 参与单位名称及 | 2024 年 11 月 19 | 日：富国基金；中信证券；中欧基金。 | ...

证券代码：300181 证券简称：佐力药业 公告编号：2024-076 浙江佐力药业股份有限公司 关于与凌意（杭州）生物科技有限公司 签署战略合作框架协议的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没 有虚假记载、误导性陈述或重大遗漏。 特别提示： 1、本次公司与合作方签署的《战略合作框架协议》属于双方合作意愿和基 本原则的框架性约定，双方后续的合作以具体签订的协议为准，具体实施内容和 进度尚存在不确定性，敬请广大投资者注意投资风险。 2、本次签署的《战略合作框架协议》不涉及具体交易金额，不会对公司本 年度经营业绩产生重大影响；对公司未来年度经营业绩的影响需视具体项目推进 和实施情况而确定。 3、公司最近三年不存在披露其他框架性协议或意向性协议的情况。 一、协议签署概况 浙江佐力药业股份有限公司（以下简称"公司"）与凌意（杭州）生物科技 有限公司（以下简称"凌意生物"）于近日签署了《战略合作框架协议》（以下 简称"本协议"），双方本着公平、平等、互利的原则，充分发挥各自优势，拟 开展长期、深度的战略合作关系。 本协议为框架性协议，不涉及实质性交易，不涉及关联交易，亦不构成 《上 市公司重 ...

证券代码：300181 证券简称：佐力药业 公告编号：2024-074 浙江佐力药业股份有限公司 2024年第一次临时股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没 有虚假记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会未出现否决议案的情形； 2、本次股东大会未涉及变更以往股东大会已通过的决议。 一、会议召开和出席情况 1、会议召集人：浙江佐力药业股份有限公司（以下简称"公司"或"本公 司 "）董事会 2、会议召开时间：（1）现场会议召开时间：2024年11月20日（星期三）下 午14:00（2）网络投票时间：通过深圳证券交易所（以下简称"深交所"）交易 系统进行网络投票的具体时间为：2024年11月20日（星期三）上午9:15—9:25， 9:30—11:30 和下午13:00—15:00；通过深交所互联网投票系统投票的具体时间 为：2024年11月20日（星期三）上午9:15至下午15:00期间的任意时间。 3、会议召开地点：浙江省德清县阜溪街道志远北路388号，浙江佐力药业股 份有限公司会议室。 4、会议召开方式：采取现场投票和网络投票相结合的方式。 5、会议主 ...

证券代码：300181 证券简称：佐力药业 公告编号：2024-075 浙江佐力药业股份有限公司 关于2024年限制性股票激励计划内幕信息知情人 买卖公司股票情况的自查报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 浙江佐力药业股份有限公司（以下简称"公司"）于2024年10月25日召开第 八届董事会第三次会议和第八届监事会第三次会议，审议通过了《关于公司<2024 年限制性股票激励计划（草案）>及其摘要的议案》等相关议案。具体内容详见 公司于2024年10月28日披露在巨潮资讯网（http://www.cninfo.com.cn）的相关 公告。 按照《上市公司股权激励管理办法》（以下简称"《管理办法》"）、《深 圳证券交易所创业板上市公司自律监管指南第1号——业务办理》等法律法规的 有关规定，公司对2024年限制性股票激励计划（以下简称"激励计划"）采取了 充分且必要的保密措施，同时对本次激励计划的内幕信息知情人进行了必要登记。 通过向中国证券登记结算有限责任公司深圳分公司查询，公司对本次激励计划内 幕信息知情人在公司《2024年限制性股票激励计划（草 ...

东方华银关于佐力药业 2024 年第一次临时股东大会的法律意见书 上海东方华银律师事务所 关于浙江佐力药业股份有限公司 2024 年第一次临时股东大会的法律意见书 致：浙江佐力药业股份有限公司 上海东方华银律师事务所（以下简称"本所"）接受浙江佐力药业股份有限 公司（以下简称"贵司"或"公司"或"上市公司"）委托，就贵司召开 2024 年第一次临时股东大会的有关事宜，根据《中华人民共和国公司法》（以下简称 "《公司法》"）、《上市公司股东大会规则》（以下简称"《大会规则》"） 等法律、法规和其他规范性文件以及《浙江佐力药业股份有限公司章程》（以下 简称"《公司章程》"）的有关规定，出具本法律意见书。 为出具本法律意见书，本所律师审查了公司提供的本次股东大会的相关资料， 包括但不限于公司召开 2024 年第一次临时股东大会的通知、公司 2024 年第一次 临时股东大会的议程、议案及决议等文件资料，同时听取了公司董事会秘书就有 关事实的陈述和说明。公司已向本所作出保证和承诺，保证公司向本所提供的资 料和文件均为真实、准确、完整，无重大遗漏。 本所律师仅就本法律意见书出具日以前所发生的事实以及本所律师对有关 法律法 ...

证券代码：300181 证券简称：佐力药业 公告编号：2024-073 浙江佐力药业股份有限公司 监事会关于2024年限制性股票激励计划激励对象 名单的公示情况说明及核查意见 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 浙江佐力药业股份有限公司（以下简称"公司"）于2024年10月25日召开第 八届董事会第三次会议和第八届监事会第三次会议，审议通过了《关于公司<2024 年限制性股票激励计划（草案）>及其摘要的议案》等相关议案。具体内容详见 公司于2024年10月28日披露在巨潮资讯网（http://www.cninfo.com.cn）的相关 公告。 按照《中华人民共和国公司法》（以下简称"《公司法》"）、《上市公司 股权激励管理办法》（以下简称"《管理办法》"）、《深圳证券交易所创业板 上市公司自律监管指南第1号——业务办理》（以下简称"《自律监管指南第1号》"） 和《公司章程》等相关规定，公司对2024年限制性股票激励计划激励对象名单在 公司内部进行了公示。公司监事会结合公示情况对激励对象进行了核查，相关公 示情况及核查情况如下： 一、公示情况及核查方 ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [6] Core Insights - The company has shown strong performance in its third-quarter report, with revenue of 2.045 billion yuan, a year-on-year increase of 39.59%, and a net profit of 421 million yuan, up 46.93% year-on-year [2] - The core products are experiencing rapid growth, particularly the traditional Chinese medicine (TCM) decoction pieces, which saw a revenue increase of 51.24% [3] - The company is focusing on the secondary development of its unique product, Wuling Capsule, for treating mild cognitive impairment, which is expected to drive further growth [4] - A stock incentive plan has been introduced, reflecting the company's confidence in future development, with performance targets set for net profit growth [5] Summary by Sections Financial Performance - For the first three quarters of 2024, the company achieved a revenue of 2.045 billion yuan, with a gross margin of 61.61% and a net margin of 20.90% [2] - The third quarter alone contributed 617 million yuan in revenue, marking a 35.97% increase year-on-year [2] Product Performance - The Wuling series sales revenue grew by 24.88%, with significant increases in the sales volume of Wuling Capsule and Lingze Tablets [3] - The sales revenue of TCM decoction pieces surged by 175.96%, indicating a strong market demand [3] Strategic Initiatives - The company is leveraging the market opportunities presented by the national policies supporting TCM, which is expected to enhance the growth of its core products [7] - The stock incentive plan aims to motivate key personnel and align their interests with the company's long-term growth objectives [5] Future Projections - The company expects revenues of 2.596 billion yuan in 2024, with net profits projected at 534 million yuan, reflecting a growth rate of 39.5% [9] - Earnings per share (EPS) are forecasted to increase to 0.76 yuan in 2024, with continued growth anticipated in subsequent years [9]

Summary of Zhaoli Pharmaceutical Conference Call Company Overview - Zhaoli Pharmaceutical focuses on the production of traditional Chinese medicine using medicinal fungi, with core products including Wuling Capsules and the Bailing series. The company's development can be divided into three phases: from 1995 to 2013, focusing on Wuling Capsules; from 2014 to 2017, attempting diversification; and from 2018 onwards, divesting non-pharmaceutical businesses to concentrate on medicinal fungi and derivatives [2][3][4] Core Products and Market Performance - Wuling Capsules are the main driver of Zhaoli Pharmaceutical's revenue growth. Due to demand expansion and centralized procurement, Wuling Capsules have seen accelerated sales. The market size is expected to reach 25.5 billion yuan by 2028, with a compound annual growth rate (CAGR) of 19% [2][5][12] - The Bailing series, centered on fermented Cordyceps powder, has high awareness in the nephrology field. Revenue from Bailing Capsules is projected to exceed 400 million yuan by 2028, with potential for replicating the growth model seen in the psychiatric department [2][6][14] Incentives and Management Confidence - On October 27, 2024, Zhaoli Pharmaceutical launched an equity incentive and employee stock ownership plan, targeting net profit growth rates of 24%, 33%, and 29% for 2025 to 2027, aiming to double net profit over three years. This reflects management's confidence in future growth and aims to enhance employee motivation and operational efficiency [2][7][11] Global and Domestic Mental Health Landscape - Globally, central nervous system (CNS) diseases, such as Alzheimer's and Parkinson's, have low mortality but high disability and recurrence rates, with over 55 million dementia patients worldwide and nearly 10 million new cases annually. In China, the aging population and the impact of the pandemic have accelerated the demand for mental health medications, indicating significant unmet needs in the market [2][8] Financial Projections - Zhaoli Pharmaceutical's projected net profits for 2024 to 2026 are 550 million yuan, 680 million yuan, and 840 million yuan, representing year-on-year growth of 43%, 25%, and 22% respectively. The target price is set at 21 yuan, with a buy rating reflecting strong future growth expectations [2][11][17] Revenue Drivers and Market Strategy - Key revenue drivers include the expansion of Wuling Capsules' demand, benefits from centralized procurement, and growth in the OTC channel. The company is also focusing on enhancing its product line through potential acquisitions in the CNS sector [2][15][20] Cost Structure and R&D Investment - Sales expenses are shifting towards OTC marketing due to centralized procurement and anti-corruption measures. Management expenses are slightly increasing due to business expansion, while R&D investments are expected to rise as the company continues to focus on medicinal fungi research [2][18] Legal Matters and Market Expansion - There are ongoing legal matters concerning Bailing Capsules, but the company remains confident that these will not significantly impact operations. Zhaoli Pharmaceutical is actively pursuing external acquisitions to expand its CNS product line [2][19][20] Regional Sales Performance - Wuling Capsules have strong sales in the Jiangsu and Zhejiang regions, with significant potential for expansion in underpenetrated areas like Northwest and North China. As of the end of 2023, the product has covered approximately 13,000 hospitals [2][21] Price Stability and Market Strategy - Currently, 21 provinces have implemented centralized procurement for Wuling Capsules, with a price of approximately 0.87 yuan per capsule. The risk of further price reductions is considered low, and the company plans to strengthen its OTC channel to ensure stable growth over the next three years [2][22][23]

Company Overview - Zhaoli Pharmaceutical's stock price reached a historical high, increasing by 3.20% to 18.37 yuan, with a trading volume of 7.5886 million shares and a transaction amount of 138 million yuan, resulting in a turnover rate of 1.26% [1] - The latest total market capitalization of Zhaoli Pharmaceutical in A-shares is 12.884 billion yuan, with a circulating market value of 11.042 billion yuan [1] Industry Performance - The pharmaceutical and biotechnology industry overall saw a rise of 1.80%, with 420 stocks increasing in price, including seven stocks hitting the daily limit, such as International Medicine and Kanghui Pharmaceutical [1] - Conversely, 63 stocks experienced price declines, with the largest drops recorded by Shuangcheng Pharmaceutical, Dongfang Ocean, and C Jianlankang, with declines of 10.00%, 8.18%, and 5.88% respectively [1] Margin Trading Data - As of November 11, the latest margin trading balance for Zhaoli Pharmaceutical is 214 million yuan, with a financing balance of 214 million yuan, reflecting an increase of 24.301 million yuan over the past ten days, representing a growth of 12.84% [1]